AT13387

DRUG4 trials

Sponsors

Astex Pharmaceuticals, Inc., National Cancer Institute (NCI)

Conditions

Breast CancerMetastatic Solid TumorsNon-small Cell Lung Cancer(NSCLC)Prostate CancerSolid Tumors

Phase 1

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

CompletedNCT00878423

Astex Pharmaceuticals, Inc.Metastatic Solid Tumors

Start: 2008-05-31End: 2014-03-31Updated: 2024-08-02

AT13387 in Adults With Refractory Solid Tumors

CompletedNCT01246102

National Cancer Institute (NCI)Breast Cancer, Solid Tumors

Start: 2010-11-19End: 2017-10-27Updated: 2018-07-05

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

CompletedNCT01685268

Astex Pharmaceuticals, Inc.Prostate Cancer

Start: 2012-09-30End: 2014-12-31Updated: 2024-08-02

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

CompletedNCT01712217

Astex Pharmaceuticals, Inc.Non-small Cell Lung Cancer(NSCLC)

Start: 2012-10-31End: 2017-05-16Updated: 2024-08-02

Related Papers

Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

Clinical Proteomics2020-02-072 citations

Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study.

Journal of Clinical Oncology2016-05-203 citations